Akebia Therapeutics
AKBA
#9606
Rank
A$0.16 B
Marketcap
A$0.58
Share price
-8.71%
Change (1 day)
-76.51%
Change (1 year)

Earnings for Akebia Therapeutics (AKBA)

Earnings in 2026 (TTM): -A$62.88 Million

According to Akebia Therapeutics's latest financial reports the company's current earnings are A$0.19 Billion. In 2025 the company made an earning of -A$5.6 Million, an increase over its 2024 earnings that were of -A$0.11 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Akebia Therapeutics from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -A$62.88 Million1024.69%
2025 -A$5.6 Million-94.64%
2024 -A$0.11 Billion33.68%
2023 -A$78.01 Million-45.12%
2022 -A$0.15 Billion-66.55%
2021 -A$0.43 Billion-26.24%
2020 -A$0.58 Billion33.94%
2019 -A$0.44 Billion66.52%
2018 -A$0.26 Billion123.53%
2017 -A$0.12 Billion-43.34%
2016 -A$0.21 Billion123.58%
2015 -A$91.22 Million63.95%
2014 -A$55.64 Million181.24%
2013 -A$19.79 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
A$28.12 B-43,455.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$18.99 B-29,379.76%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Amgen
AMGN
A$16.60 B-25,695.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
-A$0.24 Billion 254.59%๐Ÿ‡บ๐Ÿ‡ธ USA